Properties (73)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:GE_Healthcare
2010 Strategic acquisition |
| gptkbp:awards |
Various industry awards
|
| gptkbp:brand |
Established brand
|
| gptkbp:businessModel |
B2B
Sustainable growth |
| gptkbp:CEO |
gptkb:Dr._David_A._King
gptkb:David_A._King |
| gptkbp:certifications |
CLIA_certified
|
| gptkbp:clinicalTrials |
Cancer research
Ongoing Personalized medicine |
| gptkbp:communityEngagement |
Local health initiatives
|
| gptkbp:communityInvolvement |
Health awareness programs
|
| gptkbp:communityPartnerships |
Academic institutions
Strategic alliances Biotech_companies |
| gptkbp:culturalHeritage |
Collaborative environment
|
| gptkbp:customerBase |
Hospitals and clinics
|
| gptkbp:customerFeedback |
Positive testimonials
|
| gptkbp:customerService |
High ratings
|
| gptkbp:employees |
Approximately 200
|
| gptkbp:financialPerformance |
Positive growth
|
| gptkbp:financials |
Publicly traded
|
| gptkbp:focus |
Cancer diagnostics
|
| gptkbp:founded |
2005
|
| gptkbp:futurePlans |
Expand internationally
|
| gptkbp:hasResearchInterest |
Ongoing analysis
|
| gptkbp:headquarters |
gptkb:Aliso_Viejo,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Clarient, Inc.
|
| gptkbp:industry |
Healthcare
|
| gptkbp:innovation |
Diagnostic_technologies
|
| gptkbp:investmentFocus |
Various venture capital firms
|
| gptkbp:keyPeople |
gptkb:Dr._David_A._King
|
| gptkbp:leadership |
Experienced management team
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:market |
Competitive
Growing demand for diagnostics Diagnostic_testing_market |
| gptkbp:marketingStrategy |
Expand diagnostic offerings
|
| gptkbp:mission |
Improve patient outcomes
|
| gptkbp:network |
Industry connections
|
| gptkbp:partnerships |
Pharmaceutical companies
Various healthcare institutions Enhance service offerings |
| gptkbp:partOf |
gptkb:GE_Healthcare
|
| gptkbp:productLine |
Diagnostic tests
|
| gptkbp:products |
Continuous improvement
New diagnostic tests |
| gptkbp:regulatoryCompliance |
FDA_regulations
|
| gptkbp:research |
Grants and investments
|
| gptkbp:researchFocus |
Biomarker_development
|
| gptkbp:revenue |
$20 million (2010)
|
| gptkbp:serviceArea |
gptkb:North_America
|
| gptkbp:services |
Molecular diagnostics
High standards New markets |
| gptkbp:serviceType |
Laboratory services
|
| gptkbp:specializesIn |
Diagnostic_services
|
| gptkbp:stockSymbol |
CLRT
|
| gptkbp:strategicGoals |
Increase market share
|
| gptkbp:subsidiary |
gptkb:Clarient_Diagnostics_Services,_Inc.
|
| gptkbp:sustainabilityInitiatives |
Environmental responsibility
|
| gptkbp:targetMarket |
Oncologists
|
| gptkbp:technology |
Innovative solutions
Next-generation sequencing |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:training |
Ongoing education programs
|
| gptkbp:type |
Public
|
| gptkbp:vision |
Leading provider of cancer diagnostics
|
| gptkbp:website |
www.clarient.com
|